CD274 and breast cancer: In HER2-positive BC, the combination of pembrolizumab plus trastuzumab demonstrated a tolerable safety profile, activity and durable clinical benefit, in advanced HER-2-positive, trastuzumab-resistant, PD-L1-positive BC disease (33).